We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Celldex Therapeutics, Inc.
(CLDX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Celldex Therapeutics, Inc.
(CLDX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Celldex Therapeutics, Inc.
is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CLDX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLDX's full-year earnings has moved 12.54% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CLDX has returned 6.73% so far this year. Meanwhile, stocks in the Medical group have lost about 3.01% on average. This shows that Celldex Therapeutics, Inc.
is outperforming its peers so far this year.
To break things down more, CLDX belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual companies and currently sits at #16 in the Zacks Industry Rank. Stocks in this group have gained about 3.89% so far this year, so CLDX is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CLDX. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Celldex Therapeutics, Inc. (CLDX) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Celldex Therapeutics, Inc. (CLDX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Celldex Therapeutics, Inc. is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CLDX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLDX's full-year earnings has moved 12.54% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CLDX has returned 6.73% so far this year. Meanwhile, stocks in the Medical group have lost about 3.01% on average. This shows that Celldex Therapeutics, Inc. is outperforming its peers so far this year.
To break things down more, CLDX belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual companies and currently sits at #16 in the Zacks Industry Rank. Stocks in this group have gained about 3.89% so far this year, so CLDX is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CLDX. The stock will be looking to continue its solid performance.